Physician profile

Abdulrasheed Alabi

Cardiovascular Disease · Boston, MA

NPI 1013364371

$31,713.97

in general payments reported to CMS, 2019-2025

5 companies · $5,460 in 2025

The $5,460 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Grant$25,791.66
Travel and Lodging$4,407.87
Food and Beverage$857.35
Education$483.09

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $15,856.64 2023-2025 Aveir
Medtronic, INC. $9,017.47 2023-2025 Micra
Boston Scientific Corporation $5,000.00 2023-2024
Biotronik INC. $1,665.86 2025 Amvia Edge, Acticor 7 Vr-T Dx
Astellas Pharma US INC $174.00 2021-2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Abdulrasheed Alabi

$31,713.97

in general payments reported 2019-2025

Years
2021-2025
Top company
Abbott Laboratories
Context
The $5,460 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/2044690/abdulrasheed-alabi

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.